Literature DB >> 25873799

Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.

Lazaros Nikolaidis, Nabeel Memon, Brian O'Murchu.   

Abstract

We describe the case of a 54-year-old man who presented with exertional dyspnea and fatigue that had worsened over the preceding 2 years, despite a normally functioning bioprosthetic aortic valve and stable, mild left ventricular dysfunction (left ventricular ejection fraction, 0.45). His symptoms could not be explained by physical examination, an extensive biochemical profile, or multiple cardiac and pulmonary investigations. However, abnormal cardiopulmonary exercise test results and a right heart catheterization-combined with the use of a symptom-limited, bedside bicycle ergometer-revealed that the patient's exercise-induced pulmonary artery hypertension was out of proportion to his compensated left heart disease. A trial of sildenafil therapy resulted in objective improvements in hemodynamic values and functional class.

Entities:  

Keywords:  Exercise hemodynamics; exercise test; exercise tolerance; exercise-induced pulmonary hypertension; hypertension, pulmonary/diagnosis/drug therapy/etiology; phosphodiesterase 5 inhibitors/therapeutic use; pulmonary arterial hypertension; pulmonary vascular resistance; sildenafil

Mesh:

Substances:

Year:  2015        PMID: 25873799      PMCID: PMC4378044          DOI: 10.14503/THIJ-13-3671

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  22 in total

1.  Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases.

Authors:  Ronald J Oudiz; Lewis J Rubin
Journal:  Circulation       Date:  2008-11-18       Impact factor: 29.690

2.  Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Authors:  Gregory D Lewis; Justine Lachmann; Janice Camuso; John J Lepore; Jordan Shin; Maryann E Martinovic; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2006-12-18       Impact factor: 29.690

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

4.  Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis.

Authors:  Michele D'Alto; Stefano Ghio; Antonello D'Andrea; Anna Sara Pazzano; Paola Argiento; Rita Camporotondo; Francesca Allocca; Laura Scelsi; Giovanna Cuomo; Roberto Caporali; Lorenzo Cavagna; Gabriele Valentini; Raffaele Calabrò
Journal:  Heart       Date:  2010-10-03       Impact factor: 5.994

5.  Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

Authors:  Vallerie V McLaughlin; Alicia Shillington; Stuart Rich
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

6.  Exercise-induced pulmonary arterial hypertension.

Authors:  James J Tolle; Aaron B Waxman; Teresa L Van Horn; Paul P Pappagianopoulos; David M Systrom
Journal:  Circulation       Date:  2008-11-03       Impact factor: 29.690

7.  Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.

Authors:  Sebastiaan Holverda; Heleen Rietema; Harm J Bogaard; Nico Westerhof; Pieter E Postmus; Anco Boonstra; Anton Vonk-Noordegraaf
Journal:  Pulm Pharmacol Ther       Date:  2008-02-08       Impact factor: 3.410

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

10.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.

Authors:  Robin Condliffe; David G Kiely; Andrew J Peacock; Paul A Corris; J Simon R Gibbs; Florenc Vrapi; Clare Das; Charlie A Elliot; Martin Johnson; Julia DeSoyza; Chantal Torpy; Kim Goldsmith; Denise Hodgkins; Rodney J Hughes; Joanna Pepke-Zaba; J Gerry Coghlan
Journal:  Am J Respir Crit Care Med       Date:  2008-10-17       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.